Complement Activation Is Associated With Mortality in Patients With Necrotizing Soft-Tissue Infections—A Prospective Observational Study

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Complement Activation Is Associated With Mortality in Patients With Necrotizing Soft-Tissue Infections—A Prospective Observational Study. / Kristensen, Markus Korsholm; Hansen, Marco Bo; Madsen, Martin Bruun; Hansen, Cecilie Bo; Pilely, Katrine; Hyldegaard, Ole; Garred, Peter.

In: Frontiers in Immunology, Vol. 11, 17, 2020.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Kristensen, MK, Hansen, MB, Madsen, MB, Hansen, CB, Pilely, K, Hyldegaard, O & Garred, P 2020, 'Complement Activation Is Associated With Mortality in Patients With Necrotizing Soft-Tissue Infections—A Prospective Observational Study', Frontiers in Immunology, vol. 11, 17. https://doi.org/10.3389/fimmu.2020.00017

APA

Kristensen, M. K., Hansen, M. B., Madsen, M. B., Hansen, C. B., Pilely, K., Hyldegaard, O., & Garred, P. (2020). Complement Activation Is Associated With Mortality in Patients With Necrotizing Soft-Tissue Infections—A Prospective Observational Study. Frontiers in Immunology, 11, [17]. https://doi.org/10.3389/fimmu.2020.00017

Vancouver

Kristensen MK, Hansen MB, Madsen MB, Hansen CB, Pilely K, Hyldegaard O et al. Complement Activation Is Associated With Mortality in Patients With Necrotizing Soft-Tissue Infections—A Prospective Observational Study. Frontiers in Immunology. 2020;11. 17. https://doi.org/10.3389/fimmu.2020.00017

Author

Kristensen, Markus Korsholm ; Hansen, Marco Bo ; Madsen, Martin Bruun ; Hansen, Cecilie Bo ; Pilely, Katrine ; Hyldegaard, Ole ; Garred, Peter. / Complement Activation Is Associated With Mortality in Patients With Necrotizing Soft-Tissue Infections—A Prospective Observational Study. In: Frontiers in Immunology. 2020 ; Vol. 11.

Bibtex

@article{a586b700882f47ff88c3f57b489f2a0c,
title = "Complement Activation Is Associated With Mortality in Patients With Necrotizing Soft-Tissue Infections—A Prospective Observational Study",
abstract = "Aim: We assessed whether different complement factors and complement activation products were associated with poor outcome in patients with necrotizing soft-tissue infection (NSTI). Methods: We conducted a prospective, observational study in an intensive care unit where treatment of NSTI is centralized at a national level. In 135 NSTI patients and 65 control patients, admission levels of MASP-1, MASP-2, MASP-3, C4, C3, complement activation products C4c, C3bc, and terminal complement complex (TCC) were assessed. Results: The 90-day mortality was 23%. In a Cox regression model adjusted for sex, and SAPS II, a higher than median MASP-1 (HR 0.378, CI 95% [0.164–0.872], p = 0.0226) and C4 (HR 0.162, 95% CI [0.060–0.438], p = 0.0003), C4c/C4 ratio (HR 2.290 95% CI [1.078–4.867], p = 0.0312), C3bc (HR 2.664 95% CI [1.195–5.938], p = 0.0166), and C3bc/C3 ratio (HR 4.041 95% CI [1.673–9.758], p = 0.0019) were associated with 90-day mortality, while MASP-2, C4c, C3, and TCC were not. C4 had the highest ROC-AUC (0.748, [95% CI 0.649–0.847]), which was comparable to the AUC for SOFA score (0.753, [95% CI 0.649–0.857]), and SAPS II (0.862 [95% CI 0.795–0.929]). Conclusion: In adjusted analyses, high admission levels of the C4c/C4 ratio, C3bc, and the C3bc/C3 ratio were significantly associated with a higher risk of death after 90 days while high admission levels of MASP-1 and C4 were associated with lower risk. In this cohort, these variables are better predictors of mortality in NSTI than C-reactive protein and Procalcitonin. C4's ability to predict mortality was comparable to the well-established scoring systems SAPS score II and SOFA on day 1.",
keywords = "amputation, immune system, necrotizing fasciitis, sepsis, soft tissue infection, survival complement activation",
author = "Kristensen, {Markus Korsholm} and Hansen, {Marco Bo} and Madsen, {Martin Bruun} and Hansen, {Cecilie Bo} and Katrine Pilely and Ole Hyldegaard and Peter Garred",
year = "2020",
doi = "10.3389/fimmu.2020.00017",
language = "English",
volume = "11",
journal = "Frontiers in Immunology",
issn = "1664-3224",
publisher = "Frontiers Research Foundation",

}

RIS

TY - JOUR

T1 - Complement Activation Is Associated With Mortality in Patients With Necrotizing Soft-Tissue Infections—A Prospective Observational Study

AU - Kristensen, Markus Korsholm

AU - Hansen, Marco Bo

AU - Madsen, Martin Bruun

AU - Hansen, Cecilie Bo

AU - Pilely, Katrine

AU - Hyldegaard, Ole

AU - Garred, Peter

PY - 2020

Y1 - 2020

N2 - Aim: We assessed whether different complement factors and complement activation products were associated with poor outcome in patients with necrotizing soft-tissue infection (NSTI). Methods: We conducted a prospective, observational study in an intensive care unit where treatment of NSTI is centralized at a national level. In 135 NSTI patients and 65 control patients, admission levels of MASP-1, MASP-2, MASP-3, C4, C3, complement activation products C4c, C3bc, and terminal complement complex (TCC) were assessed. Results: The 90-day mortality was 23%. In a Cox regression model adjusted for sex, and SAPS II, a higher than median MASP-1 (HR 0.378, CI 95% [0.164–0.872], p = 0.0226) and C4 (HR 0.162, 95% CI [0.060–0.438], p = 0.0003), C4c/C4 ratio (HR 2.290 95% CI [1.078–4.867], p = 0.0312), C3bc (HR 2.664 95% CI [1.195–5.938], p = 0.0166), and C3bc/C3 ratio (HR 4.041 95% CI [1.673–9.758], p = 0.0019) were associated with 90-day mortality, while MASP-2, C4c, C3, and TCC were not. C4 had the highest ROC-AUC (0.748, [95% CI 0.649–0.847]), which was comparable to the AUC for SOFA score (0.753, [95% CI 0.649–0.857]), and SAPS II (0.862 [95% CI 0.795–0.929]). Conclusion: In adjusted analyses, high admission levels of the C4c/C4 ratio, C3bc, and the C3bc/C3 ratio were significantly associated with a higher risk of death after 90 days while high admission levels of MASP-1 and C4 were associated with lower risk. In this cohort, these variables are better predictors of mortality in NSTI than C-reactive protein and Procalcitonin. C4's ability to predict mortality was comparable to the well-established scoring systems SAPS score II and SOFA on day 1.

AB - Aim: We assessed whether different complement factors and complement activation products were associated with poor outcome in patients with necrotizing soft-tissue infection (NSTI). Methods: We conducted a prospective, observational study in an intensive care unit where treatment of NSTI is centralized at a national level. In 135 NSTI patients and 65 control patients, admission levels of MASP-1, MASP-2, MASP-3, C4, C3, complement activation products C4c, C3bc, and terminal complement complex (TCC) were assessed. Results: The 90-day mortality was 23%. In a Cox regression model adjusted for sex, and SAPS II, a higher than median MASP-1 (HR 0.378, CI 95% [0.164–0.872], p = 0.0226) and C4 (HR 0.162, 95% CI [0.060–0.438], p = 0.0003), C4c/C4 ratio (HR 2.290 95% CI [1.078–4.867], p = 0.0312), C3bc (HR 2.664 95% CI [1.195–5.938], p = 0.0166), and C3bc/C3 ratio (HR 4.041 95% CI [1.673–9.758], p = 0.0019) were associated with 90-day mortality, while MASP-2, C4c, C3, and TCC were not. C4 had the highest ROC-AUC (0.748, [95% CI 0.649–0.847]), which was comparable to the AUC for SOFA score (0.753, [95% CI 0.649–0.857]), and SAPS II (0.862 [95% CI 0.795–0.929]). Conclusion: In adjusted analyses, high admission levels of the C4c/C4 ratio, C3bc, and the C3bc/C3 ratio were significantly associated with a higher risk of death after 90 days while high admission levels of MASP-1 and C4 were associated with lower risk. In this cohort, these variables are better predictors of mortality in NSTI than C-reactive protein and Procalcitonin. C4's ability to predict mortality was comparable to the well-established scoring systems SAPS score II and SOFA on day 1.

KW - amputation

KW - immune system

KW - necrotizing fasciitis

KW - sepsis

KW - soft tissue infection

KW - survival complement activation

U2 - 10.3389/fimmu.2020.00017

DO - 10.3389/fimmu.2020.00017

M3 - Journal article

C2 - 32082310

AN - SCOPUS:85079635532

VL - 11

JO - Frontiers in Immunology

JF - Frontiers in Immunology

SN - 1664-3224

M1 - 17

ER -

ID: 254461407